Achieve Better Outcomes
BVA helps end the debate by taking the guesswork out of determining a patient’s
volume status to significantly improve multiple measures of patient outcomes.
Significantly Reduce Heart Failure Mortality & Readmissions
Propensity matched-control trial in community hospital | n = 245, Mixed HFpEF/HFrEF
(P<0.001)
(P<0.001)
(P<0.001)
Blood Volume Measurements Improved ICU Survival
Prospective randomized control trial in surgical ICU | n = 100, 70% Septic Shock/Sepsis/40% ARDS
(P=0.03)
(P=0.14)
36 Hour Earlier
Treatment Decision
44% Change in Treatment
Strategy Versus Standard Care
Excellent Value in Healthcare
Blood Volume-Guided Treatment Extremely Cost-Effective
Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF
Well above the 0.227 previously reported
Than far below the threshold of $50,000
Approved for Reimbursement
Where Daxor BVA-100 Blood Test Makes an Impact
Watch Our Story
In the Spotlight
Watch Daxor CEO, Michael Feldschuh, Discuss How BVA-100 Technology is Joining to Fight COVID-19